We are live on
!
Find out more
BI
BVF Inc Portfolio holdings
AUM
$3.14B
1-Year Est. Return
249.53%
This Fund
S&P 500
This Quarter
Est. Return
+56.08%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.97B
AUM Growth
+$504M
(+20%)
Cap. Flow
-$339M
Cap. Flow
% of AUM
-11.43%
Top 10 Holdings %
Top 10 Hldgs %
62.79%
Holding
48
New
2
Increased
8
Reduced
8
Closed
7
Top Buys
| 1 |
Xencor
XNCR
|
+$65.6M |
| 2 |
Disc Medicine
IRON
|
+$54.9M |
| 3 |
Invivyd
IVVD
|
+$40.6M |
| 4 |
Stoke Therapeutics
STOK
|
+$18.3M |
| 5 |
CBIO
Crescent Biopharma
CBIO
|
+$17.3M |
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
+$170M |
| 2 |
CDTX
Cidara Therapeutics
CDTX
|
+$135M |
| 3 |
Axsome Therapeutics
AXSM
|
+$61.6M |
| 4 |
SEPN
Septerna Inc
SEPN
|
+$54.8M |
| 5 |
Revolution Medicines
RVMD
|
+$40.5M |
Sector Composition
| 1 | Healthcare | 99.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Kymera Therapeutics
KYMR
$9.31B
| $428M | 14.41% |
5,502,710
| – | – |
|
|
2
Revolution Medicines
RVMD
$38.9B
| $267M | 9% |
3,356,782
-618,131
| -16% | -$40.5M |
|
3
MoonLake Immunotherapeutics
MLTX
$1.63B
| $260M | 8.76% |
19,751,284
| – | – |
|
4
Structure Therapeutics
GPCR
$3.46B
| $242M | 8.15% |
3,479,022
+275,105
| +9% | +$11.2M |
|
5
Olema Pharmaceuticals
OLMA
$1.05B
| $132M | 4.46% |
5,295,893
| – | – |
|
6
Mirum Pharmaceuticals
MIRM
$7.28B
| $118M | 3.98% |
1,495,290
| – | – |
|
7
GH Research
GHRS
$1.82B
| $112M | 3.77% |
8,827,712
| – | – |
|
|
8
Xencor
XNCR
$1.1B
| $109M | 3.68% |
7,133,720
+4,393,579
| +160% | +$65.6M |
|
9
Zymeworks
ZYME
$1.82B
| $104M | 3.49% |
3,938,641
| – | – |
|
|
PVLA
10
Palvella Therapeutics
PVLA
$2.21B
| $92M | 3.1% |
879,009
-282,240
| -24% | -$24.1M |
|
11
Kura Oncology
KURA
$1B
| $89.5M | 3.01% |
8,617,162
| – | – |
|
|
12
Stoke Therapeutics
STOK
$1.83B
| $71.9M | 2.42% |
2,265,674
+608,578
| +37% | +$18.3M |
|
13
Xoma
XOMA
| $68.9M | 2.32% |
2,590,303
| – | – |
|
|
ABVX
14
Abivax
ABVX
$11.9B
| $68.5M | 2.31% |
508,031
-50,000
| -9% | -$5.46M |
|
15
Nektar Therapeutics
NKTR
$2.26B
| $65.9M | 2.22% |
1,559,595
+283,000
| +22% | +$15.8M |
|
16
AC Immune
ACIU
$241M
| $62.2M | 2.1% |
19,822,436
| – | – |
|
17
Monte Rosa Therapeutics
GLUE
$1.98B
| $60.1M | 2.02% |
3,835,886
-1,824,246
| -32% | -$24.6M |
|
18
Cullinan Oncology
CGEM
$1.09B
| $59.5M | 2% |
5,750,683
| – | – |
|
19
Tyra Biosciences
TYRA
$1.9B
| $55.9M | 1.88% |
2,127,665
-1,522,129
| -42% | -$28M |
|
|
20
Disc Medicine
IRON
$2.87B
| $51.6M | 1.74% |
+650,000
| New | +$54.9M |
|
21
Immunocore
IMCR
$1.7B
| $50.3M | 1.69% |
1,488,975
-85,313
| -5% | -$3.01M |
|
|
22
Invivyd
IVVD
$228M
| $48.2M | 1.62% |
+19,525,000
| New | +$40.6M |
|
|
SEPN
23
Septerna Inc
SEPN
$1.53B
| $48M | 1.61% |
1,720,782
-2,295,008
| -57% | -$54.8M |
|
24
Annexon
ANNX
$922M
| $45.8M | 1.54% |
9,128,080
+2,128,080
| +30% | +$8.14M |
|
25
Compass Therapeutics
CMPX
$384M
| $41.7M | 1.4% |
7,764,842
+3,014,842
| +63% | +$13.9M |
|
Similar funds
GKWIM
LT
BP
SC
AWE
EAM
HIMCH
SCM